RecruitingNCT07175922

Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease

Evaluation of csgA Prevalence, Gene Expression and Week-to-Week Variability in Participants With Parkinson's Disease and a History of Gastrointestinal Dysfunction

Sponsor

Vertero Therapeutics

Enrollment

200 participants

Start Date

Sep 25, 2025

Study Type

OBSERVATIONAL

Conditions

Parkinsons Disease (PD)

Summary

This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria5

Between 18-80 years of age at ICF signing (inclusive)
A diagnosis of PD within 10 years from the time of ICF signing
Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment
All participants must understand and provide written informed consent prior to any study specific procedures
Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments

Exclusion Criteria5

Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance
Recent GI infection in the past 3 months if deemed clinically significant by the investigator.
Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator
Any known current or past eating disorder if deemed clinically significant by the investigator
Use of systemic antibiotics within 6 months prior to enrollment